Introduction to Our Research Opportunity
CardioClone is excited to announce recently being awarded funding to perform pre-clinical research aimed at eliminating transplant rejection. We are exploring two pathways: HLA gene deactivation via lentivirus Cas-9 therapy and engineering chimeric bone marrow using CD34+ cells.
HLA Gene Deactivation
One approach aims to reduce the risk of transplant rejection by modifying the human leukocyte antigen (HLA) genes. By deactivating these genes, we hope to create a more favorable environment for transplant acceptance, ultimately improving patient outcomes.
Engineering Chimeric Bone Marrow
In addition to HLA gene deactivation, we are also investigating the potential of engineering chimeric bone marrow via CD34 cells. This innovative approach involves the use of hematopoietic stem cells (CD34 cells) to create a chimeric bone marrow environment that can better accommodate transplanted tissues or organs. Our goal is to reduce the likelihood of transplant rejection and enhance the overall success rate of transplant procedures.
Join Us in Our Research Endeavor
We are currently accepting applications from researchers who are eager to contribute to this vital pre-clinical research. This funded research project explores CD34+ cell engineering for chimeric bone marrow to address transplant rejection. Our evaluation of various methods aims for publication in a peer-reviewed journal, advancing the field towards developing safe, effective approaches for long-term immune tolerance in transplant patients.
If you are interested in joining us in this endeavor, please apply now. Together, we can pave the way for a future where transplant rejection is a challenge of the past.
Email: Austin@CardioClone.com